PepGen Inc. (PEPG)
2.52
-0.18
(-6.67%)
USD |
NASDAQ |
Oct 23, 16:00
2.53
+0.01
(+0.40%)
After-Hours: 20:00
PepGen Enterprise Value : 73.39M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 73.39M |
| October 22, 2026 | 85.86M |
| October 21, 2026 | 87.24M |
| October 20, 2026 | 97.63M |
| October 19, 2026 | 85.86M |
| October 16, 2026 | 78.93M |
| October 15, 2026 | 74.08M |
| October 14, 2026 | 59.54M |
| October 13, 2026 | 72.00M |
| October 12, 2026 | 71.31M |
| October 09, 2026 | 80.31M |
| October 08, 2026 | 63.69M |
| October 07, 2026 | 65.08M |
| October 06, 2026 | 58.84M |
| October 05, 2026 | 62.31M |
| October 02, 2026 | 56.77M |
| October 01, 2026 | 51.92M |
| September 30, 2026 | 66.46M |
| September 29, 2026 | 60.92M |
| September 28, 2026 | 78.24M |
| September 25, 2026 | 78.24M |
| September 24, 2026 | 84.47M |
| September 23, 2026 | 87.24M |
| September 22, 2026 | 105.25M |
| September 21, 2026 | 95.55M |
| Date | Value |
|---|---|
| September 18, 2026 | 96.24M |
| September 17, 2026 | 104.56M |
| September 16, 2026 | 99.71M |
| September 15, 2026 | 99.02M |
| September 14, 2026 | 104.56M |
| September 11, 2026 | 105.25M |
| September 10, 2026 | 108.02M |
| September 09, 2026 | 117.02M |
| September 08, 2026 | 121.18M |
| September 04, 2026 | 114.25M |
| September 03, 2026 | 119.10M |
| September 02, 2026 | 119.10M |
| September 01, 2026 | 114.94M |
| August 31, 2026 | 105.94M |
| August 28, 2026 | 112.17M |
| August 27, 2026 | 111.48M |
| August 26, 2026 | 121.87M |
| August 25, 2026 | 136.07M |
| August 24, 2026 | 119.79M |
| August 21, 2026 | 116.33M |
| August 20, 2026 | 109.06M |
| August 19, 2026 | 110.10M |
| August 18, 2026 | 100.40M |
| August 17, 2026 | 109.40M |
| August 14, 2026 | 105.94M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
| Sangamo Therapeutics, Inc. | 39.39M |
| Sarepta Therapeutics, Inc. | 2.130B |
| Anixa Biosciences, Inc. | 88.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.81M |
| Total Expenses (Quarterly) | 17.81M |
| EPS Diluted (Quarterly) | -0.2574 |
| Earnings Yield | -51.81% |
| Normalized Earnings Yield | -51.81 |